^
    Apply
    Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. (NCT03544723)
    Phase 2
    MultiVir, Inc.
    Recruiting
    Last update posted :
    06/09/2020
    Initiation :
    10/01/2018
    Primary completion :
    06/30/2022
    Completion :
    12/31/2022
    TP53
    |
    TP53 mutation • TP53 wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Ad-p53 gene therapy